 |
answer text |
<p>The United Kingdom national action plan for antimicrobial resistance (AMR), published
on 24 January, includes the commitment to lead the way in testing innovative models
that pay companies for antibiotics based primarily on a health technology assessment
of their value to the National Health Service, as opposed to the volumes used.</p><p>This
project was formally launched by the National Institute for Health and Care Excellence
and NHS England and NHS Improvement on 9 July.</p><p>A period of targeted engagement
to secure stakeholder input into the development of key areas of the project, including
the proposed approach for topic selection, the approach to evaluation, and the outline
commercial model was launched on 9 July and concluded on 6 September 2019.</p><p>The
next stages will involve the development of an evaluation framework and commercial
model, selection of products to be included in the test and undertaking a value assessment
for the selected products.</p><p>It is anticipated that payments will be implemented
to companies from spring 2021 following commercial negotiation with companies.</p><p>
</p>
|
|
